关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
  Y- z8 q, _3 Z7 z    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
7 s+ S9 w7 ^# r, F7 C- v8 }  U
# Z( ?7 s7 o5 @作者：来自澳大利亚
来源：Haematologica. 2011.8.9.
Dear Group,
$ h$ U! T2 G' e: J7 M* p
# V# k% d. H. v) ZSome of you are on Dasatinib (Sprycel) and we wish to give news on all CML
therapies. Here is a report from Australia on 3 patients who went off Sprycel
after stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
& N1 Z% ?5 t% l2 L9 p2 Iremain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
does spike up the immune system so I hope more reports come out on this issue.
  @/ U4 x" [1 ~# Z6 M- c
3 `/ |9 s$ m; z: ~- ]The remarkable news about Sprycel cessation is that all 3 patients had failed
Gleevec and Sprycel was their second TKI so they had resistant disease. This is
! a2 {) K. }, G. ]# g$ wdifferent from the stopping Gleevec trial in France which only targets patients
who have done well on Gleevec.

, k- i( F( D  q: F( cHopefully, the doctors will report on a larger study and long-term to see if the
( u* m8 @5 _& h) a4 I, kresponse off Sprycel is sustained.
* D% n3 q6 S# b$ I# ?" D
8 Z8 e+ p# E0 ]+ Q6 r" y/ ZBest Wishes,
$ w7 y* ^% m) M0 r, p/ T2 m0 j/ _Anjana
* w8 h6 O+ @1 e3 R2 O$ E& N
5 \9 X6 P* B& k2 b
& p7 D% f. i5 {- G0 j% e
Haematologica. 2011 Aug 9. [Epub ahead of print]
Durable complete molecular remission of chronic myeloid leukemia following
dasatinib cessation, despite adverse disease features.
, q2 i4 K# @' o3 E7 Z; _0 yRoss DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
Source
Adelaide, Australia;

Abstract
+ k/ d" _5 E0 dPatients with chronic myeloid leukemia, treated with imatinib, who have a
- s$ J2 w) h1 t! n1 q6 Gdurable complete molecular response might remain in CMR after stopping
) J/ x: R& i1 R6 vtreatment. Previous reports of patients stopping treatment in complete molecular
response have included only patients with a good response to imatinib. We
describe three patients with stable complete molecular response on dasatinib
treatment following imatinib failure. Two of the three patients remain in
0 L% m, s  h# }% r# V; S% _5 x* Xcomplete molecular response more than 12 months after stopping dasatinib. In
these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
show that the leukemic clone remains detectable, as we have previously shown in
imatinib-treated patients. Dasatinib-associated immunological phenomena, such as
the emergence of clonal T cell populations, were observed both in one patient
9 n6 [6 C" Y/ K* Y" V3 Qwho relapsed and in one patient in remission. Our results suggest that the
characteristics of complete molecular response on dasatinib treatment may be
9 `1 q! ^( t% R4 {+ n& s5 `similar to that achieved with imatinib, at least in patients with adverse
$ ?, F+ _! W7 `* c! K7 ^disease features.
* k8 I5 ?/ }- T/ L6 Y( L1 X

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
6 F, a, c% b( ]6 T' T1 A& R    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。
. Q# U' u$ _9 m, B4 M3 x# E( s
2 [. k4 B. ]' g3 o作者：来自法国STIM试验
1 u7 d) J/ g3 C+ ^" M来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事